Drug Database
SA

saxagliptin (Bessin)

✓ Approved

Sino Biopharmaceutical Co., Ltd · DPP4 · 小分子

什么是 saxagliptin?

saxagliptin 是一种小分子,由Sino Biopharmaceutical Co., Ltd研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Bessin
公司Sino Biopharmaceutical Co., Ltd
药物类别小分子
分子靶点DPP4
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

saxagliptin 作用于 1 个分子靶点:

DPP4dipeptidyl peptidase 4 (CD26, DPPIV)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

saxagliptin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedEye (London, England)2026-11-19

Incidence and visual outcomes of post-intravitreal injection endophthalmitis: a single-centre analysis of 224,397 injections.

Kayikci Mahmutoglu Gulce G, Simsek Metehan M, Cevik Sadik Gorkem SG, Arici Murat M et al.

Post-injection endophthalmitis (PIE) is a rare, vision-threatening complication of intravitreal injections (IVIs). As IVI volumes rise globally, optimising prevention and management is crucial. This study evaluated PIE incidence, risk factors, microbiology, and outcomes over ten years. A retrospective cohort study of 224,397 IVIs. We analysed demographics, agent type, and preparation (pre-filled syringe [PFS] vs. manual aliquoting). Overall endophthalmitis incidence was 0.029% (n = 65), and 0.026% for anti-VEGFs. PFS-ranibizumab had the lowest incidence (0.014%) and was significantly safer than manually prepared bevacizumab (0.039%; OR: 2.74 [95% CI: 1.36-5.55], p = 0.003); vial-sourced aflibercept (0.027%) was intermediate and not statistically distinguishable from either. Culture positivity was 33.8% (n = 22), predominantly Gram-positive (81.8%), with Staphylococcus epidermidis being the most common (45.5%). In univariate analysis, culture positivity was the sole predictor of worse final visual acuity (VA) (p = 0.030), though limited by small sample sizes. Median VA worsened from 0.61 logMAR at baseline to 2.10 logMAR at presentation, recovering to 1.80 logMAR at final visit (p < 0.001). Among cases initially treated with tap and intravitreal antibiotics (TAI), 60% (21/35) required subsequent vitrectomy (PPV). No baseline clinical parameters predicted TAI success or PPV requirement (all p > 0.05). Dexamethasone implants, with their larger applicator, carried the highest risk. Among anti-VEGFs, PFS ranibizumab demonstrated the most favourable safety profile, with the lowest incidence of PIE. Manual immediate-use bevacizumab aliquoting is a safe, cost-effective alternative in resource-limited settings. In univariate analysis, culture positivity emerged as a negative prognostic factor, though this finding is limited by small sample sizes. Given unpredictable TAI responses, aggressive monitoring and a low PPV threshold are essential.

PMID 43052414
阅读全文 →
PubMedBMC gastroenterology2026-11-19

Diagnostic performance of quantitative ultrasound techniques for the diagnosis and grading of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis.

Liu Xingya X, Liu Funing F, Zhai Xuechao X, Liu Wenrui W et al.

Quantitative ultrasound-derived techniques are core non-invasive tools assessing liver steatosis in metabolic dysfunction-associated steatotic liver disease (MASLD), providing direct fat fraction measurements for screening, grading, and monitoring. This study compares the diagnostic performance of varied quantitative ultrasound-derived approaches relative to magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) via a network meta-analysis (NMA). PubMed, Embase, the Cochrane Library, and Web of Science were systematically searched until December 7, 2025, for English diagnostic accuracy studies comparing quantitative ultrasound-based techniques with MRI-PDFF for MASLD grading. The primary outcomes extracted were sensitivity (SEN) and specificity (SPE). Study quality was assessed via the QUADAS-2 tool. The primary analysis employed a Bayesian arm-based bivariate random-effects network meta-analysis of diagnostic accuracy implemented in RStan, jointly estimating the pooled SEN, pooled SPE, diagnostic odds ratio (DOR), and superiority index (SI) of each technique within the same model. In addition, exploratory univariate network meta-analyses were performed for SEN and SPE separately using gemtc to calculate the relative sensitivity, relative specificity, and corresponding SUCRA values. Seventeen studies from 10 countries were included, comprising 1,904 MASLD patients and 1,041 controls and covering 17 quantitative ultrasound-derived techniques. The overall risk of bias (RoB) was moderately low. Except for the SEN analysis of S1 steatosis, no significant publication bias was detected across the remaining grading analyses, although evidence of small-study effects was observed. The bivariate random-effects model demonstrated that SWA (0.96), UDFF (0.92), and TAI (0.98) achieved the highest SEN for diagnosing S1, S2, and S3 steatosis, respectively (e.g., S1 (mild):≥S1 vs. S0, S2 (moderate):≥S2 vs. S0-S1, S3 (severe):≥S3 vs. S0-S2). For SPE, RFM + ACE + HI showed superior performance for S1 (0.95) and S2 (0.91), whereas UDFF/Deep-USFF demonstrated the highest SPE for S3 steatosis (0.89). The superiority index, which comprehensively evaluates overall diagnostic performance, showed that RFM + ACE+HI performed remarkably well in S1 (SI = 14.25) and S2 (SI = 15.72), whereas Deep-USFF showed excellent performance in S3 (SI = 14.61). The diagnostic odds ratios indicated that SWA exhibited the highest DOR in S1 (373,719.55, 95% CrI: 8.08-853,672.04) and S2 (234.01, 95% CrI: 1.86-1,077.23), while TAI showed the highest DOR in S3 (2,498,255.36, 95% CrI: 34.43-1,309,055.51). Some estimates were accompanied by extremely wide credible intervals (owing to zero-event studies), indicating uncertainty and warranting cautious interpretation. This NMA indicates that quantitative ultrasound-derived techniques exhibit distinct diagnostic strengths for grading hepatic steatosis in MASLD. SWA, UDFF, and TAI demonstrated superior SEN for detecting mild (S1), moderate (S2), and severe (S3) steatosis, respectively, whereas RFM + ACE + HI and UDFF/Deep-USFF showed greater SPE for their corresponding steatosis grades. This study relied primarily on the composite indicators from the bivariate model as the core basis for evaluation, with some indicators exhibiting certain uncertainties due to the presence of zero-event studies. The SUCRA values calculated based on SEN and SPE separately reflect only the relative ranking of a single diagnostic indicator and cannot independently represent the overall diagnostic performance. Future high-quality, multicenter studies are still needed to validate the clinical utility of different quantitative ultrasound techniques in the screening and staging of MASLD.

PMID 43052783
阅读全文 →
PubMedBMC chemistry2026-11-19

Extractive ion-pair spectrophotometric methods utilizing bromocresol green to estimate chlorpheniramine maleate in pharmaceutical formulations.

Murshed Fatima A FA, Al-Mawri Siham H A SHA, Abdulrahman Sameer A M SAM

Two accurate, sensitive, and cost-effective spectrophotometric methods were developed and validated for the quantitative determination of Chlorpheniramine Maleate (CPM). Method A is based on the formation of a yellow ion-pair complex between CPM and bromocresol green (BCG) in an acidic medium. The resulting complex is extracted into dichloromethane, and its absorbance is measured at 414 nm. Method B involves the dissociation of the yellow-colored CPM-BCG ion-pair complex in a basic medium, leading to the development of a blue color that gives a maximum absorbance at 618 nm. Beer's law was found to be valid within the concentration ranges of 1.00-25.0 µg/mL for method A and 0.20-9.00 µg/mL for method B. The molar absorptivities were determined and found to be 1.76 × 104 and 4.47 × 104 L/(mol.cm) for methods A and B, respectively, with Sandell sensitivity values of 0.0222 and 0.0087 µg/cm². Detection and quantification limits were determined and found to be 0.2049 and 0.6210 µg/mL for method A, and 0.0199 and 0.0603 µg/mL for method B, respectively. The linearity was excellent with correlation coefficients of 0.9995 and 0.9997 for methods A and B. The developed methods were successfully employed to determine CPM in both its pure form and commercial pharmaceutical formulations. The methods were highly precise, with relative standard deviations between 0.24% and 1.85%, and highly accurate, with recovery percentages ranging from 98.14% to 100.8% when applied to pharmaceutical formulations. Statistical comparison with the official USP HPLC method showed no significant differences in accuracy or precision, making the developed methods ideal for routine quality control in resource-limited settings.

PMID 43053190
阅读全文 →
PubMedEssays in biochemistry2026-11-19

The donated chemical probe programme: advancing biomedical research through open science.

Haeberle Sandra S, Tredup Claudia C

Chemical probes enable selective modulation of protein function in live cells, making them valuable tools for studying the roles of proteins in normal and disease physiology. Although initiatives such as the chemical probe development programme at the Structural Genomics Consortium have expanded access to chemial probes for selected target classes, the general availability across the druggable proteome remains limited, particularly for compounds developed within the pharmaceutical industry. The donated chemical probe (DCP) programme addresses this gap through an open-science model that combines unrestricted access to donated probes with comprehensive characterisation data and independent expert review. Since its launch in 2017, the programme has become an important resource for basic as well as translational research. More than 20 organisations have contributed to the initiative, resulting in a collection of about 140 chemical probes together with matched control compounds and previously inaccessible characterisation data that had often remained confined to patents or internal reports. The present review summarises recent developments of the DCP programme and highlights representative examples including case studies such as the BUB1 chemical probe BAY 1816032.

PMID 43053520
阅读全文 →
PubMedFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026-11-19

Chronic Oral Trehalose Intake Induces Sex-Dependent Hippocampal Dysfunction and Cognitive Impairment in Healthy Mice.

Camazzola Davide D, Tomasicchio Barbara B, Serrao Simone S, Pistella Aurora A et al.

Trehalose is a naturally occurring nonreducing disaccharide widely distributed across diverse organisms, where it serves as both a stress protectant and an energy source. Although vertebrates lack the ability to synthesize trehalose, its expanding use in the food, pharmaceutical, and cosmetic industries has led to a marked, unintentional increase in dietary intake. In mammals, trehalose is only partially hydrolyzed, and emerging evidence indicates that a fraction of unmetabolized trehalose can enter systemic circulation, cross the blood-brain barrier, and influence metabolic processes, gut microbiota composition, and potentially brain function. Notably, trehalose has been identified as an inducer of autophagy and has shown efficacy in several models of neurodegenerative diseases. Given its increasing consumption and potential impact on the central nervous system, this study investigates the effects of chronic oral trehalose intake in healthy mice. Using a multidisciplinary approach encompassing behavioral analyses, metabolomics, and ex vivo and in vivo assessments of neuronal function, we demonstrate that prolonged trehalose consumption impairs spatial cognition and associative memory and induces structural, functional, and lipidomic alterations in the brain. These effects exhibit a marked sex-dependent pattern, predominantly affecting male mice. Importantly, these changes occur without significant modulation of autophagy in the brain, suggesting that alternative mechanisms may underlie the observed effects of trehalose on neuronal physiology. Overall, despite its widespread use and GRAS classification, prolonged trehalose intake may adversely affect brain physiology and cognition in a sex-dependent manner.

PMID 43053575
阅读全文 →
PubMedPharmacotherapy2026-11-19

Antiplatelet Use in the Setting of Therapeutic Anticoagulation: A Scoping Review.

Ammar Amina A, Edwin Stephanie B SB, Reed Jason B JB, Kaatz Scott S et al.

Patients receiving therapeutic oral anticoagulation (OAC) often have indications for antiplatelet therapy. Historically, antiplatelet agents have been used alongside therapeutic anticoagulation, increasing the risk of bleeding without a proven reduction in thrombosis. This scoping review summarizes recent evidence evaluating OAC monotherapy compared with combination therapy consisting of OAC plus antiplatelet agent among patients with atrial fibrillation and stable coronary artery disease, cerebrovascular disease, and prosthetic heart valves. We searched PubMed, Embase, CENTRAL, and International Pharmaceutical Abstracts to identify randomized controlled trials (RCTs) evaluating these strategies. Included studies enrolled adults receiving therapeutic anticoagulation across different cardiovascular disease states that reported efficacy and safety outcomes. Two reviewers independently screened studies and extracted data, with disagreements resolved by a third reviewer. Published subgroup analyses of included RCTs were also reviewed. After screening 10,008 records, 11 RCTs met inclusion criteria. Evidence supporting OAC monotherapy was observed in patients with atrial fibrillation and stable coronary artery disease; OAC monotherapy consistently reduced bleeding without increasing ischemic events compared with combination therapy. Similar reductions in bleeding were observed in patients with cerebrovascular disease, although evidence remains limited by small sample size and early trial termination. Among patients undergoing transcatheter aortic valve replacement with an indication for chronic anticoagulation, OAC monotherapy reduced bleeding without compromising ischemic outcomes. Evidence supporting discontinuation of antiplatelet therapy in patients with mechanical heart valves remains limited. Additional RCTs are needed to better define the role of antiplatelet therapy in cerebrovascular disease, prosthetic heart valves, and other high-risk populations.

PMID 43053629
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多saxagliptin